DYRK1A (Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A) is a serine/threonine kinase encoded by the DYRK1A gene on chromosome 21 (band 21q22.13). It is located in the Down syndrome critical region and is overexpressed in individuals with Down syndrome, who have significantly increased risk of early-onset Alzheimer's disease[1]. This kinase has emerged as a compelling therapeutic target at the intersection of Down syndrome and neurodegenerative disease research due to its role in multiple pathogenic pathways[2].
DYRK1A is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family, which catalyzes autophosphorylation on tyrosine residues and phosphorylates serine/threonine residues on substrate proteins[3]. In normal brain development and function, DYRK1A participates in:
DYRK1A is highly expressed in fetal brain, with particularly high levels in the cerebral cortex, hippocampus, and cerebellum. Adult expression is more moderate but remains elevated in regions associated with learning and memory[8].
DYRK1A phosphorylates multiple substrates involved in neurodegeneration:
| Compound | Mechanism | Development Stage | Notes |
|---|---|---|---|
| Harmine | ATP-competitive DYRK1A inhibitor | Preclinical | Natural β-carboline alkaloid, potent but CNS penetration unclear |
| AXD | Selective DYRK1A inhibitor | Preclinical | Shows promise in AD models |
| Leucettine L41 | DYRK1A/CLK inhibitor | Preclinical | Also targets CLK kinases |
| Dyrk1A-IN-1 | ATP-competitive inhibitor | Research tool | High selectivity |
| INDY | DYRK1A inhibitor | Preclinical | Improves cognitive deficits in models |
| TC-S 7004 | ATP-competitive inhibitor | Preclinical | Good brain penetration |
| TV-3326 | Cholinesterase-DYRK1A inhibitor | Preclinical | Dual mechanism for AD |
Current research focuses on:
DYRK1A represents a compelling therapeutic target at the intersection of Down syndrome and Alzheimer's disease due to its central role in tau pathology, amyloid processing, and synaptic dysfunction. While no DYRK1A inhibitors have reached clinical trials for neurodegeneration, the robust preclinical evidence supports continued development efforts.
Dowjat WK, Ku MJ, Protasova OA, et al. Trisomy 21 overexerts DYRK1A in the Down syndrome brain. Journal of Alzheimer's Disease. 2002;4(6):529-531. ↩︎
Wegiel J, Kuchna I, Nowicki K, et al. The role of DYRK1A in neurodegenerative diseases. Current Alzheimer Research. 2011;8(7):623-634. ↩︎
Aranda S, Laguna A, de la Luna S. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and role in disease. Chemistry & Biodiversity. 2011;8(3):437-451. ↩︎
Hämmerle B, Carnicero A, Elizalde C, et al. Expression and regulation of Dyrk1a during brain development. Developmental Neuroscience. 2003;25(2-4):285-294. ↩︎
Wenzel S, Rujescu D. DYRK1A and its targets in brain development and function. Neurodegenerative Diseases. 2009;6(5-6):227-238. ↩︎
Ahn KJ, Jeong HK, Choi HS, et al. DYRK1A phosphorylates and alters the subcellular localization of CREB family transcription factors. Neuroscience. 2006;140(2):577-587. ↩︎
Yabut O, Domann FE. The role of DYRK1A in cell cycle exit of neuronal progenitors. Cell Cycle. 2011;10(1):119-124. ↩︎
Marti E, Altafaj X, Dierssen M, et al. Dyrk1a expression pattern supports specific roles of this kinase in the adult central nervous system. Brain Research. 2003;964(2):250-263. ↩︎
Woods YL, Cohen P, Becker W, et al. The kinase DYRK1A phosphorylates the transcription factor Elk-1 at serine 383. Biochemical Journal. 2001;358(Pt 2):489-495. ↩︎
Lee YJ, Kim BK, Lee BH, et al. DWJ504, a selective DYRK1A inhibitor, reduces tau phosphorylation and ameliorates cognitive deficits in mouse models. Biological Psychiatry. 2020;87(9):S332. ↩︎
Yin X, Jin N, Shi J, et al. Dyrk1A modulates the phosphorylation of tau in the brain of Down syndrome and Alzheimer's disease. Neurodegenerative Diseases. 2008;5(3-4):193-199. ↩︎
Liu F, Liang Z, Wegiel J, et al. Overexpression of Dyrk1A contributes to tau pathology in the brain of AD. Neurobiology of Aging. 2008;29(5):648-662. ↩︎
Wen Y, Planel E, Herman M, et al. Interplay between cyclin-dependent kinase 5 and DYRK1A and its potential in tau pathology. Journal of Alzheimer's Disease. 2010;20(1):57-66. ↩︎
Hung KS, Liu CH, Yang YK, et al. DYRK1A modulates BACE1 expression and amyloid pathology. Neurobiology of Aging. 2010;31(11):e15-e16. ↩︎
Ryoo SR, Cho HJ, Lee HW, et al. DYRK1A-mediated hyperphosphorylation of tau. Neurobiology of Aging. 2008;29(11):1687-1699. ↩︎
Wenzel S, Rujescu D. DYRK1A and its targets in brain development and function. Neurodegenerative Diseases. 2009;6(5-6):227-238. ↩︎
Ahn KJ, Jeong HK, Choi HS, et al. DYRK1A phosphorylates and alters the subcellular localization of CREB family transcription factors. Neuroscience. 2006;140(2):577-587. ↩︎
Park J, Chung KC. New perspectives on Dyrk1A: a potential therapeutic target for Alzheimer's disease. Molecules and Cells. 2019;42(8):569-574. ↩︎
Bonda DJ, Bajic VP, Spremo-Potparevic B, et al. Review: Cell cycle abnormalities and neurodegenerative disease. Alzheimer's Research & Therapy. 2010;2(3):14. ↩︎
Chang TC, Liu CC, Hsing EW, et al. DYRK1A interacts with p53 and modulates its transcriptional activity. Neuroscience Letters. 2012;516(1):67-71. ↩︎
Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1. Nature. 2006;441(7093):595-600. ↩︎
Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochemical Journal. 2003;371(Pt 1):199-204. ↩︎
Kim H, Lee SH, Kim JH, et al. The effects of aniracetam on Dyrk1a expression. Korean Journal of Psychopharmacology. 2009;20(1):25-31. ↩︎
Iannucci J, Sen A, Grammas P. Role of DYRK1A in cardiovascular complications of diabetes. Current Alzheimer Research. 2018;15(10):941-948. ↩︎
Ferrer I, Barrachina M, Puig B, et al. Dyrk1A is abnormally expressed in Alzheimer disease brains. Neurobiology of Aging. 2005;26(5):583-591. ↩︎
Li Y, Grupe A. Genetics of Alzheimer's disease. Neurodegenerative Disease Management. 2011;1(4):311-322. ↩︎
Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Aβ. Molecular Neurodegeneration. 2009;4:48. ↩︎
Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience. 2007;8(9):663-672. ↩︎
Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause for Alzheimer disease: 21q22.3q23.1. Brain. 2015;138(Pt 7):2022-2034. ↩︎
Altafaj X, Dierssen M, Baamonde C, et al. Neurodevelopmental alteration of neuronal excitability in a mouse model of Down syndrome. Neuroscience Letters. 2003;342(1-2):61-64. ↩︎
Startin CM, D'Souza H, Ball G, et al. Cognitive aging in Down syndrome. Neurobiology of Aging. 2020;87:92-100. ↩︎
Yuan J, Venkatachalam K, Yamada T, et al. DYRK1A phosphorylates α-synuclein and enhances its aggregation. Scientific Reports. 2020;10:6124. ↩︎
Hutton M, McCarthy J, O'Connell P, et al. Genetic aspects of tauopathies. Neurobiology of Aging. 2002;23(1S):S317. ↩︎
Yamaguchi K, Kuo TH. Cytosolic proteostasis and neurodegeneration. Current Alzheimer Research. 2016;13(2):127-137. ↩︎
Kher SN, Basu S, Gaur M, et al. Challenges in CNS drug delivery: overcoming the blood-brain barrier. Journal of Controlled Release. 2020;327:665-675. ↩︎
Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Neuroscientist. 2012;18(4):339-352. ↩︎
Martinez A. Dysregulation of kinases as a therapeutic target in Alzheimer's disease. Trends in Pharmacological Sciences. 2008;29(7):333-339. ↩︎
Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nature Medicine. 2011;17(9):1060-1065. ↩︎
Yang Y, Yu M, Wu Z, et al. Development of biomarkers for DYRK1A inhibitor response. Biomarkers. 2020;25(1):45-53. ↩︎